Modality
mRNA
MOA
KRASG12Ci
Target
JAK1
Pathway
Complement
SMARBPNH
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
~Apr 2022
→ ~Jul 2023
Phase 2
Oct 2023
→ Apr 2029
Phase 2Current
NCT07412178
2,212 pts·SMA
2023-10→2029-04·Terminated
2,212 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-093.0y awayPh2 Data· SMA
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2
Termina…
Catalysts
Ph2 Data
2029-04-09 · 3.0y away
SMA
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07412178 | Phase 2 | SMA | Terminated | 2212 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| ALN-6288 | Alnylam | Approved | LAG-3 |